Business Context and Reporting Period
Company: Vital Therapies, Inc. (Note: Metadata listed "IMMUNIC, INC." but the filing text identifies Vital Therapies, Inc.)
Filing Type: Form 8-K (Current Report)
Date: May 6, 2014
Context: The company reported the full exercise of the underwriters' option to purchase additional shares following its initial public offering (IPO).
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share purchase transaction:
- Additional Shares Purchased: 675,000 shares of common stock
- Price Per Share: $12.00 (IPO price, less underwriting discount)
- Transaction Status: Option exercised in full
Material Changes
The material change reported is the increase in outstanding common stock and capital raised due to the underwriters exercising their over-allotment option in full. No other material changes to operations or financial position are detailed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies beyond the announcement of the share purchase. The document serves solely to disclose the completion of the underwriters' option exercise.
Investor Verification Checklist
- Verify the total number of shares outstanding post-exercise of the over-allotment option.
- Confirm the net proceeds received from the sale of the 675,000 additional shares after deducting the underwriting discount.
- Review the attached Press Release (Exhibit 99.1) for any additional context regarding the use of proceeds.